scholarly journals Color perception differentiates Alzheimer's Disease (AD) from Vascular Dementia (VaD) patients

2017 ◽  
Vol 29 (8) ◽  
pp. 1355-1361 ◽  
Author(s):  
N. A. Arnaoutoglou ◽  
M. Arnaoutoglou ◽  
P. Nemtsas ◽  
V. Costa ◽  
S. J. Baloyannis ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Vascular Dementia ◽  
Color Vision ◽  
Color Blindness ◽  
Age Related Macular Degeneration ◽  
Control Group ◽  
Close Link ◽  
Age Related ◽  
Color Vision Test

ABSTRACTBackground:Alzheimer's Disease (AD) and Vascular Dementia (VaD) are the most common causes of dementia in older people. Both diseases appear to have similar clinical symptoms, such as deficits in attention and executive function, but specific cognitive domains are affected. Current cohort studies have shown a close relationship between αβ deposits and age-related macular degeneration (Johnson et al., 2002; Ratnayaka et al., 2015). Additionally, a close link between the thinning of the retinal nerve fiber (RNFL) and AD patients has been described, while it has been proposed that AD patients suffer from a non-specific type of color blindness (Pache et al., 2003).Methods:Our study included 103 individuals divided into three groups: A healthy control group (n = 35), AD (n = 32) according to DSM-IV-TR, NINCDS-ADRDA criteria, and VaD (n = 36) based on ΝΙΝDS-AIREN, as well as Magnetic Resonance Imaging (MRI) results. The severity of patient's cognitive impairment, was measured with the Mini-Mental State Examination (MMSE) and was classified according to the Reisberg global deterioration scale (GDS). Visual perception was examined using the Ishihara plates: “Ishihara Color Vision Test - 38 Plate.”Results:The three groups were not statistically different for demographic data (age, gender, and education). The Ishihara color blindness test has a sensitivity of 80.6% and a specificity of 87.5% to discriminate AD and VaD patients when an optimal (32.5) cut-off value of performance is used.Conclusions:Ishihara Color Vision Test - 38 Plate is a promising potential method as an easy and not time-consuming screening test for the differential diagnosis of dementia between AD and VaD.

scholarly journals Color vision test to differentiate Alzheimer's disease from vascular dementia

2017 ◽  
Vol 29 (10) ◽  
pp. 1753-1753 ◽  
Author(s):  
Tomoyuki Kawada
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Differential Diagnosis ◽  
Vascular Dementia ◽  
Color Vision ◽  
Color Blindness ◽  
Diagnosis Of Dementia ◽  
Color Vision Test ◽  
Sensitivity Specificity ◽  
Differential Diagnosis Of Dementia

Arnaoutoglou et al. (2017) reported that “Ishihara Color Vision Test – 38 Plate” was useful for the differential diagnosis of dementia between Alzheimer's Disease (AD) and Vascular Dementia (VaD). The authors used sensitivity/specificity analysis, presenting 80.6% and 87.5% to discriminate AD and VaD patients when an optimal (32.5) cut-off value of performance was used. The authors cited a reference of the fact that AD patients suffered from a non-specific type of color blindness (Pache et al., 2003), and I have a query on their study with special reference to statistical method.

Preclinical Cognitive Trajectories Differ for Alzheimer's Disease and Vascular Dementia

2012 ◽  
Vol 18 (2) ◽  
pp. 191-199 ◽  
Author(s):  
Erika J. Laukka ◽  
Stuart W.S. MacDonald ◽  
Laura Fratiglioni ◽  
Lars Bäckman
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Vascular Dementia ◽  
Early Stage ◽  
Block Design ◽  
Word Recall ◽  
Cognitive Tasks ◽  
Control Group ◽  
Age Related ◽  
Preclinical Ad

AbstractWe investigated differences between Alzheimer's disease (AD) and vascular dementia (VaD) from the appearance of the first cognitive symptoms, focusing on both time of onset and rate of accelerated decline for different cognitive functions before dementia diagnosis. Data from a longitudinal population-based study were used, including 914 participants (mean age = 82.0 years, SD = 5.0) tested with a cognitive battery (word recall and recognition, Block Design, category fluency, clock reading) on up to four occasions spanning 10 years. We fit a series of linear mixed effects models with a change point to the cognitive data, contrasting each dementia group to a control group. Significant age-related decline was observed for all five cognitive tasks. Relative to time of diagnosis, the preclinical AD persons deviated from the normal aging curve earlier (up to 9 years) compared to the preclinical VaD persons (up to 6 years). However, once the preclinical VaD persons started to decline, they deteriorated at a faster rate than the preclinical AD persons. The results have important implications for identifying the two dementia disorders at an early stage and for selecting cognitive tasks to evaluate treatment effects for persons at risk of developing AD and VaD. (JINS, 2012, 18, 191–199)

scholarly journals Suppression of AMD-Like Pathology by Mitochondria-Targeted Antioxidant SkQ1 Is Associated with a Decrease in the Accumulation of Amyloid β and in mTOR Activity

Antioxidants ◽  
2019 ◽  
Vol 8 (6) ◽  
pp. 177 ◽  
Author(s):  
Natalia A. Muraleva ◽  
Oyuna S. Kozhevnikova ◽  
Anzhela Z. Fursova ◽  
Nataliya G. Kolosova
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Amyloid Β ◽  
Developed Countries ◽  
Term Treatment ◽  
Age Related Macular Degeneration ◽  
Eye Health ◽  
Age Related ◽  
Long Term Treatment

Age-related macular degeneration (AMD) is a major cause of irreversible visual impairment and blindness in developed countries, and the molecular pathogenesis of AMD is poorly understood. Recent studies strongly indicate that amyloid β (Aβ) accumulation —found in the brain and a defining feature of Alzheimer’s disease—also forms in the retina in both Alzheimer’s disease and AMD. The reason why highly neurotoxic proteins of consistently aggregate in the aging retina, and to what extent they contribute to AMD, remains to be fully addressed. Nonetheless, the hypothesis that Aβ is a therapeutic target in AMD is debated. Here, we showed that long-term treatment with SkQ1 (250 nmol/[kg body weight] daily from the age of 1.5 to 22 months) suppressed the development of AMD-like pathology in senescence-accelerated OXYS rats by reducing the level of Aβ and suppressing the activity of mTOR in the retina. Inhibition of mTOR signaling activity, which plays key roles in aging and age-related diseases, can be considered a new mechanism of the prophylactic effect of SkQ1. It seems probable that dietary supplementation with mitochondria-targeted antioxidant SkQ1 can be a good prevention strategy to maintain eye health and possibly a treatment of AMD.

scholarly journals Brevican and Neurocan Peptides as Potential Cerebrospinal Fluid Biomarkers for Differentiation Between Vascular Dementia and Alzheimer’s Disease

2020 ◽  
pp. 1-13
Author(s):  
Karolina Minta ◽  
Gunnar Brinkmalm ◽  
Erik Portelius ◽  
Per Johansson ◽  
Johan Svensson ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Vascular Dementia ◽  
Extracellular Enzymes ◽  
Control Group ◽  
Healthy Controls ◽  
Clear Trend ◽  
Cerebrospinal Fluid Biomarkers

Background: Brevican and neurocan are central nervous system-specific extracellular matrix proteoglycans. They are degraded by extracellular enzymes, such as metalloproteinases. However, their degradation profile is largely unexplored in cerebrospinal fluid (CSF). Objective: The study aim was to quantify proteolytic peptides derived from brevican and neurocan in human CSF of patients with Alzheimer’s disease (AD) and vascular dementia (VaD) compared with controls. Methods: The first cohort consisted of 75 individuals including 25 patients with AD, 7 with mild cognitive impairment (MCI) diagnosed with AD upon follow-up, 10 patients with VaD or MCI diagnosed with VaD upon follow-up, and 33 healthy controls and cognitively stable MCI patients. In the second cohort, 31 individuals were included (5 AD patients, 14 VaD patients and 12 healthy controls). Twenty proteolytic peptides derived from brevican (n = 9) and neurocan (n = 11) were quantified using high-resolution parallel reaction monitoring mass spectrometry. Results: In the first cohort, the majority of CSF concentrations of brevican and neurocan peptides were significantly decreased inVaDas compared withADpatients (AUC = 0.83.0.93, p≤0.05) and as compared with the control group (AUC = 0.79.0.87, p ≤ 0.05). In the second cohort, CSF concentrations of two brevican peptides (B87, B156) were significantly decreased in VaD compared with AD (AUC = 0.86.0.91, p ≤ 0.05) and to controls (AUC = 0.80.0.82, p ≤ 0.05), while other brevican and neurocan peptides showed a clear trend to be decreased in VaD compared with AD (AUC = 0.64.80, p > 0.05). No peptides differed between AD and controls. Conclusion: Brevican and neurocan peptides are potential diagnostic biomarkers for VaD, with ability to separate VaD from AD.

scholarly journals Age-Related Macular Degeneration (AMD): Alzheimer's Disease in the Eye?

2011 ◽  
Vol 24 (4) ◽  
pp. 615-631 ◽  
Author(s):  
Kai Kaarniranta ◽  
Antero Salminen ◽  
Annakaisa Haapasalo ◽  
Hilkka Soininen ◽  
Mikko Hiltunen
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Age Related

Association of Alzheimer's disease and age‐related macular degeneration

2011 ◽  
Vol 89 (s248) ◽  
pp. 0-0
Author(s):  
K TOTH‐KOVACS ◽  
Z PAMER ◽  
O RIDEG ◽  
A KOVACS ◽  
S FEKETE ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Age Related

scholarly journals Nutritional status of selenium in Alzheimer's disease patients

2009 ◽  
Vol 103 (6) ◽  
pp. 803-806 ◽  
Author(s):  
Bárbara Rita Cardoso ◽  
Thomas Prates Ong ◽  
Wilson Jacob-Filho ◽  
Omar Jaluul ◽  
Maria Isabel d'Ávila Freitas ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Nutritional Status ◽  
Neuronal Degeneration ◽  
Hydride Generation ◽  
Control Group ◽  
Food Record ◽  
Age Related ◽  
Normal Cognitive Function ◽  
Dietary Food

Studies have shown that various antioxidants are decreased in different age-related degenerative diseases and thus, oxidative stress would have a central role in the pathogenesis of many disorders that involve neuronal degeneration, including Alzheimer's disease (AD). The present study aimed to assess the nutritional status of Se in AD patients and to compare with control subjects with normal cognitive function. The case–control study was carried out on a group of elderly with AD (n 28) and compared with a control group (n 29), both aged between 60 and 89 years. Se intake was evaluated by using a 3-d dietary food record. Se was evaluated in plasma, erythrocytes and nails by using the method of hydride generation atomic absorption spectroscopy. Deficient Se intake was largely observed in the AD group. AD patients showed significantly lower Se levels in plasma, erythrocytes and nails (32·59 μg/l, 43·74 μg/l and 0·302 μg/g) when compared with the control group (50·99 μg/l, 79·16 μg/l and 0·400 μg/g). The results allowed us to suggest that AD has an important relation with Se deficiency.

scholarly journals Beta-Amyloid Precursor Protein (βAPP) Processing in Alzheimer’s Disease (AD) and Age-Related Macular Degeneration (AMD)

2014 ◽  
Vol 52 (1) ◽  
pp. 533-544 ◽  
Author(s):  
Yuhai Zhao ◽  
Surjyadipta Bhattacharjee ◽  
Brandon M. Jones ◽  
James M. Hill ◽  
Christian Clement ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Amyloid Precursor Protein ◽  
Macular Degeneration ◽  
Beta Amyloid ◽  
Precursor Protein ◽  
Age Related Macular Degeneration ◽  
Age Related
Sign in / Sign up

Export Citation Format

Share Document